ASH Clinical News ACN_5.5_full_issue_web | Page 7

For patients with previously treated CLL/SLL or B-cell NHL, LOXO ONCOLOGY IS RESEARCHING A NEW STRATEGY TO ADDRESS RESISTANCE AND INTOLERANCE TO COVALENT BTK INHIBITORS * > NOW ENROLLING Investigation into selective non-covalent BTK inhibition may expand possibilities for patients previously treated with a covalent BTK inhibitor LOXO-305 is an investigational, selective non-covalent BTK inhibitor currently in clinical development, with preclinical potency against both wild-type and cysteine-481–mutated BTK (C481S) and improved selectivity compared with other BTK inhibitors. 1 STUDY DESIGN NCT03740529: A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or B-cell NHL Secondary Outcome Measures: Phase 1: Phase 2: • Safety • ORR as assessed by the Investigator • Best overall response • PK • ORR • Duration of response • Progression-free survival • Overall survival BTK=Bruton’s tyrosine kinase; BTKi=Bruton’s tyrosine kinase inhibitor; CLL=chronic lymphocytic leukemia; DLBCL=diffuse large B-cell lymphoma; FL=follicular lymphoma; MCL=mantle cell lymphoma; MTD=maximum tolerated dose; MZL=marginal zone lymphoma; NHL=non-Hodgkin’s lymphoma; ORR=overall response rate; PK=pharmacokinetics; RP2D=recommended phase 2 dose; R/R=relapsed/refractory; SLL=small lymphocytic leukemia; WM=Waldenström macroglobulinemia. * eg, Imbruvica® (ibrutinib) and Calquence® (acalabrutinib). † Prior treatment with any number of approved or investigational covalent or non-covalent BTK inhibitors is allowed. Reference: 1. Data on file. BTK001. 2018; Loxo Oncology, Inc. Primary Outcome Measures: Phase 1: MTD/RP2D Phase 2: ORR as assessed by an Independent Review Committee Titration to therapeutic dose based on PK Identification of MTD/RP2D A phase 1/2, open-label, first-in-human study designed to evaluate LOXO-305 in patients with previously treated CLL/SLL, WM/MCL/MZL, FL, DLBCL, or other B-cell NHL. Histologically confirmed CLL/SLL and B-cell NHL Histologically confirmed CLL/SLL and B-cell NHL R/R disease, +/- prior BTKi † , CLL/SLL, WM/MCL/MZL, FL, DLBCL, or other B-cell NHL: wild-type and C481-mutant, or other patients with clinical rationale For full eligibility requirements, please visit ClinicalTrials.gov For more information about enrolling a patient or to participate as a trial site, visit LoxoBTKtrials.com or call 1-855-LOXO-305. Copyright © Loxo Oncology, Inc, 2018, All Rights Reserved. LMA-US-BTK-122018-00001 Imbruvica ® is a registered trademark of Pharmacyclics LLC and Janssen Biotech, Inc. Calquence ® is a registered trademark of AstraZeneca.